These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38385191)

  • 1. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and
    Antequera CM; Orleck K; Jacob R; Kenneally A; Wright WL
    Postgrad Med; 2024 Mar; 136(2):131-140. PubMed ID: 38385191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
    Gisbert JP; Piqué JM
    Med Clin (Barc); 2005 May; 124(18):697-709. PubMed ID: 15899166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanism of corpus-predominant gastritis after PPI therapy in Helicobacter pylori-positive patients with GERD.
    Mukaisho K; Hagiwara T; Nakayama T; Hattori T; Sugihara H
    World J Gastroenterol; 2014 Sep; 20(34):11962-5. PubMed ID: 25232231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
    Kuipers EJ; Klinkenberg-Knol EC; Meuwissen SG
    Yale J Biol Med; 1999; 72(2-3):211-8. PubMed ID: 10780583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP; Wu TS; Dan YY
    J Clin Pharm Ther; 2015 Aug; 40(4):368-75. PubMed ID: 25893507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori and gastroesophageal reflux disease: friends or foes?
    Gisbert JP; Pajares JM; Losa C
    Hepatogastroenterology; 1999; 46(26):1023-9. PubMed ID: 10370661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
    Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
    Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the clinical influence of Helicobacter pylori in effective acid suppression-implications for the treatment of gastro-oesophageal reflux disease.
    Martínek J; Kuzela L; Spicák J; Vavrecka A
    Aliment Pharmacol Ther; 2000 Aug; 14(8):979-90. PubMed ID: 10930891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroesophageal reflux disease and the relationship with Helicobacter pylori.
    Mungan Z; Pınarbaşı Şimşek B
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S61-S67. PubMed ID: 29199171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
    Ghoshal UC; Blaachandran A; Rai S; Misra A
    Indian J Gastroenterol; 2022 Aug; 41(4):405-414. PubMed ID: 35771390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to inhibition of gastric acid secretion.
    Sachs G; Shin JM; Hunt R
    Curr Gastroenterol Rep; 2010 Dec; 12(6):437-47. PubMed ID: 20924727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].
    Choi YJ
    Korean J Gastroenterol; 2022 Dec; 80(6):247-253. PubMed ID: 36567437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful
    Shinozaki S; Osawa H; Hayashi Y; Miura Y; Yano T; Lefor AK; Yamamoto H
    Scand J Gastroenterol; 2022 Jan; 57(1):16-21. PubMed ID: 34547219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection.
    Sarnelli G; Ierardi E; Grasso R; Verde C; Bottiglieri ME; Nardone G; Budillon G; Cuomo R
    Dig Liver Dis; 2003 Mar; 35(3):151-6. PubMed ID: 12779068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.